Literature DB >> 24513262

Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.

Jacques Sarles1, Roch Giorgi2, Patrice Berthézène3, Anne Munck4, David Cheillan5, Jean-Charles Dagorn3, Michel Roussey6.   

Abstract

BACKGROUND: French health authorities promoted a study on 553,167 newborns comparing the performances of IRT/DNA and IRT/PAP for CF newborn screening.
METHODS: In parallel to IRT/DNA, PAP was assayed in newborns with IRT>50 μg/L. Provisional PAP cutoffs at 3.0 μg/L when 50<IRT<100 μg/L and 1.7 μg/L when IRT>100 were used. Positive newborns were subjected to sweat test. Optimal cutoffs were established by a non-inferiority method.
RESULTS: 95 CF newborns were identified (83 classical forms (ClF), including 9 meconium ileus (MI), and 12 atypical (mild) forms (AF) Of them, IRT/DNA identified 85 (73 ClF including 5 MI and 12 AF). PAP cutoffs at 1.8 μg/L when 50< IRT<100 μg/L and 0.6 μg/L when IRT>100 μg/L would identify 82 CF: 77 ClF, including 8 MI, and 5 AF. The number of sweat tests was 314 and 1039 in the IRT/DNA and IRT/PAP strategies, respectively.
CONCLUSIONS: Using the optimal cutoffs, the sensitivity of the IRT/PAP strategy would not be inferior to that of IRT/DNA if identification of MF is not required.
Copyright © 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR; Cystic fibrosis; IRT; Neonatal screening; Non-inferiority; PAP

Mesh:

Substances:

Year:  2014        PMID: 24513262     DOI: 10.1016/j.jcf.2014.01.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  8 in total

1.  Newborn Screening for Cystic Fibrosis in Mersin Province: Yearly Assessment of the National Program.

Authors:  Ali Özdemir; Dilek Doğruel
Journal:  Turk Thorac J       Date:  2020-03-01

2.  Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth.

Authors:  Yu-Chung Lin; Katherine Keenan; Jiafen Gong; Naim Panjwani; Julie Avolio; Fan Lin; Damien Adam; Paula Barrett; Stéphanie Bégin; Yves Berthiaume; Lara Bilodeau; Candice Bjornson; Janna Brusky; Caroline Burgess; Mark Chilvers; Raquel Consunji-Araneta; Guillaume Côté-Maurais; Andrea Dale; Christine Donnelly; Lori Fairservice; Katie Griffin; Natalie Henderson; Angela Hillaby; Daniel Hughes; Shaikh Iqbal; Jennifer Itterman; Mary Jackson; Emma Karlsen; Lorna Kosteniuk; Lynda Lazosky; Winnie Leung; Valerie Levesque; Émilie Maille; Dimas Mateos-Corral; Vanessa McMahon; Mays Merjaneh; Nancy Morrison; Michael Parkins; Jennifer Pike; April Price; Bradley S Quon; Joe Reisman; Clare Smith; Mary Jane Smith; Nathalie Vadeboncoeur; Danny Veniott; Terry Viczko; Pearce Wilcox; Richard van Wylick; Garry Cutting; Elizabeth Tullis; Felix Ratjen; Johanna M Rommens; Lei Sun; Melinda Solomon; Anne L Stephenson; Emmanuelle Brochiero; Scott Blackman; Harriet Corvol; Lisa J Strug
Journal:  Genet Med       Date:  2021-01-26       Impact factor: 8.822

3.  Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.

Authors:  Anne Munck; Dominique Delmas; Marie-Pierre Audrézet; Lydie Lemonnier; David Cheillan; Michel Roussey
Journal:  J Med Screen       Date:  2017-04-28       Impact factor: 2.136

4.  Mortality Due to Cystic Fibrosis over a 36-Year Period in Spain: Time Trends and Geographic Variations.

Authors:  Ana Villaverde-Hueso; Germán Sánchez-Díaz; Francisco J Molina-Cabrero; Elisa Gallego; Manuel Posada de la Paz; Verónica Alonso-Ferreira
Journal:  Int J Environ Res Public Health       Date:  2019-01-04       Impact factor: 3.390

Review 5.  Pancreatitis-Associated Protein in Neonatal Screening for Cystic Fibrosis: Strengths and Weaknesses.

Authors:  Olaf Sommerburg; Jutta Hammermann
Journal:  Int J Neonatal Screen       Date:  2020-03-30

6.  Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters.

Authors:  Maximilian Zeyda; Andrea Schanzer; Pavel Basek; Vera Bauer; Ernst Eber; Helmut Ellemunter; Margit Kallinger; Josef Riedler; Christina Thir; Franz Wadlegger; Angela Zacharasiewicz; Sabine Renner
Journal:  Diagnostics (Basel)       Date:  2021-02-13

7.  Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience.

Authors:  Chiara Bianchimani; Daniela Dolce; Claudia Centrone; Silvia Campana; Novella Ravenni; Tommaso Orioli; Erica Camera; Gianfranco Mergni; Cristina Fevola; Paolo Bonomi; Giovanni Taccetti; Vito Terlizzi
Journal:  Int J Neonatal Screen       Date:  2022-08-03

8.  Screening for cystic fibrosis in New York State: considerations for algorithm improvements.

Authors:  Denise M Kay; Breanne Maloney; Rhonda Hamel; Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Emily McGrath; Lea Krein; Beth Vogel; Carlos A Saavedra-Matiz; Michele Caggana; Norma P Tavakoli
Journal:  Eur J Pediatr       Date:  2015-08-21       Impact factor: 3.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.